Tag: Metastatic Breast Cancer

Researchers have identified that cytosolic EZH2 functionally inactivates Rb to drive CDK4/6 inhibitor resistance in ER-positive, HER2-negative metastatic breast cancer, ...

The SYMPHA study protocol outlines three parallel randomised trials evaluating electronic symptom monitoring and wearable activity tracking across 454 metastatic ...

A systematic review and meta-analysis found that adding immune checkpoint inhibitors to chemotherapy significantly improves progression-free survival, but not overall ...

A retrospective cohort study found that androgen receptor expression and the androgen-to-estrogen receptor ratio did not independently predict progression-free survival ...

A study in Breast Cancer Research finds that BRCA1/2 carriers with HER2-negative metastatic breast cancer exhibit distinct metastatic patterns, including ...

A cross-sectional study finds that low concordance between patient and physician reporting of symptoms is associated with worse health-related quality ...

A retrospective cohort study found that FDG-PET detected heterogeneous treatment responses in thirty percent of metastatic breast cancer follow-up examinations, ...

A retrospective Indian analysis of 101 patients reports real-world efficacy and safety outcomes for the trastuzumab emtansine biosimilar UJVIRA in ...

A single-center study of 21 patients found that trastuzumab emtansine produced no responses and a median progression-free survival of 2.20 ...

An indirect comparison finds sacituzumab govitecan and datopotamab deruxtecan comparable in progression control, but only sacituzumab govitecan has direct randomized ...

A University of Michigan study of two independent cohorts found that patients with lobular metastatic breast cancer are far more ...

A 2026 correspondence questions the robustness of reported links between neighborhood deprivation, metastatic breast cancer genomics, targeted treatment use and ...

A retrospective study of 103 patients with HER2-positive de novo metastatic breast cancer found that those who underwent breast surgery ...

A retrospective cohort study of 123 patients suggests the oral fluoropyrimidine S-1 may deliver longer overall survival than capecitabine as ...

A real-world cohort of 126 Chinese patients shows trastuzumab deruxtecan delivers a median 9.1 months of progression-free survival in HER2-low ...

A multicenter Central European real-world study finds sacituzumab govitecan delivers meaningful survival benefit and manageable toxicity in heavily pretreated metastatic ...

In the labyrinthine journey of metastatic breast cancer (mBC), treatment decisions are notoriously complex, influenced by a matrix of medical, ...

Over the past few decades, medical advancements in cancer treatment have significantly changed the landscape for patients, particularly those diagnosed ...